CBF Cord Blood Forum

A continuously changing selection of articles

  1. Recent Reviews

    Citation #1. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, Loberiza FR, Champlin RE, Klein JP, Horowitz MM, Wagner JE. Lancet. 2007;9;369(9577): 1947-54.

    Citation #2. Expanding the role of umbilical cord blood transplantation. Brunstein CG, Setubal DC, Wagner JE. Br J Haematol. 2007;137:20-35.
  1. Multi-Cord Transplants

    Citation #2. Double umbilical cord blood transplantation. Majhail NS, Brunstein CG, Wagner JE. Curr Opin Immunol. 2006; 18: 1-5.

    Citation #1. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, Miller JS, Blazar BR, McGlave PB, Wagner JE. Blood. 2007;110:3064-3070.

  2. Reduced Intensity and Non-Myeloablative Transplants

    Citation #2. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ. Biol Blood Marrow Transplant. 2008;14:282-9.

  3. Donor Selection for Unrelated Cord Blood Transplantation

    Citation #2. Donor selection for unrelated cord blood transplants. Gluckman E, Rocha V. Curr Opin Immunol. 2006; 18:565-70
  1. Graft-Versus-Host Disease

    Citation #2. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Arora M, Nagaraj S, Wagner JE, Barker JN, Brunstein CG, Burns LJ, Defor TE, McMillan ML, Miller JS, Weisdorf DJ. Biol Blood Marrow Transplant. 2007;13:1145-52.

    [NOTE: These citations are among a plethora of articles that continue to emerge indicating that GVHD, especially extensive chronic GVHD, is significantly more frequent after PBSC and less easily treated than after cord blood transplants. Although PBSC grafts provide a number of advantages, the high rate of GVHD, especially chronic GVHD, is of such serious concern as to suggest re-consideration of this source of stem cells for HSCT. . For further details concerning this important point and about GVHD following CBT see: Annotated Bibliography VIII, Graft-versus Host Disease, citations 2, 3 & 4. Also see: Annotated Bibliography VIII, Graft-versus Host Disease, i Graft versus host disease in BMT and PBSC hematopoietic cell transplants, citations #1, 11, 12, 13, 14 and 17.]

  2. HLA

    Citation #3. Hematopoietic stem cell donor selection: the Europdonor experience. Oudshoorn M, van Walraven SM, Bakker JN, Lie JL, V D Zanden HG, Heemskerk MB, Claas FH. Hum Immunol. 2006; 67:405-412.
  1. Cord Blood Banking i. Overview

    Citation #1. Eleven million donors in Bone Marrow Donors Worldwide! Time for reassessment? van Rood JJ, Oudshoorn M. Bone Marrow Transplant. 2008;41:1-9. Is it cost-effective to continue to add donors to the adult registries? (Clue: the Sorcerer’s Apprentice has been invoked as a colorful answer to this question.)

    Citation #2. Use of cost-effectiveness analysis to determine inventory size for a national cord blood bank. Howard DH et al. Med Decis Making. 2008;28:243-253.